MOTS-C · DECODED
MOTS-c
Decoded · Grey Market · Mitochondrial-Derived Peptide
BY THE NUMBERS
HOW IT WORKS
A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, the first mitochondria-derived peptide (mitokine) shown to act as a systemic signaling molecule. Activates AMPK, improving insulin sensitivity and mitochondrial substrate utilization. Also translocates to the nucleus under metabolic stress to regulate gene expression. No completed human interventional trials exist.
WHERE IT CAME FROM
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide with an unusual origin: it is encoded in the mitochondrial genome, not the nuclear genome where most peptides are encoded. Mitochondria, the organelles that produce cellular energy, retain a small genome from their bacterial ancestors. MOTS-c was first identified in 2015 by the Pincus Chan laboratory at the University of Southern California, which recognized that the mitochondrial genome was producing biologically active peptide signals rather than just the ribosomal RNA it had been thought to exclusively encode.
MOTS-c functions as a retrograde signal (a message from the mitochondria to the nucleus and to other tissues) that regulates metabolic stress responses, insulin sensitivity, and cellular energy balance. In animal models, MOTS-c increases exercise capacity, improves insulin sensitivity, reduces age-related metabolic decline, and extends lifespan in some models. These effects have led to its classification as a potential exercise mimetic, a compound that produces some of the metabolic benefits of physical exercise. WADA added MOTS-c to its prohibited list in 2024, which reflects the sports regulatory body's assessment that it has significant performance-enhancing potential, even without completed Phase 3 data.
THE STUDIES
WHAT THE STUDIES SHOW
ESTABLISHED (ANIMAL)
- ▸Insulin sensitivity improvement in mouse models
- ▸Exercise capacity enhancement in animal studies
- ▸Age-related metabolic decline reduction in mice
- ▸Lifespan extension in some animal aging models
HUMAN (OBSERVATIONAL ONLY)
- ▸Circulating MOTS-c correlates with metabolic health
- ▸Centenarian populations show distinct MOTS-c profiles
- ▸Exercise acutely raises endogenous MOTS-c
- ▸Correlation ≠ causation: supplementation not tested
UNKNOWN
- ▸Whether injectable MOTS-c produces metabolic benefit in humans
- ▸Effective dose, route, and timing
- ▸Long-term safety at grey market doses
- ▸Whether human longevity is influenced by exogenous MOTS-c
SIDE EFFECTS
REPORTED (ANECDOTAL)
- ▸Injection site reactions
- ▸Reported improved energy and recovery in grey market users
- ▸No systematic adverse event data from controlled studies
NOTABLE / MONITOR FOR
- ▸WADA banned (2024): prohibited in all competitive sport
- ▸Grey market supply: purity, sterility, and concentration unverified
- ▸No long-term safety data from controlled studies
- ▸Metabolic effects at supraphysiologic doses are unknown
REGULATORY STATUS
MOTS-c was on the FDA's Category 2 prohibited list for 503A compounding. On April 15, 2026, the FDA removed MOTS-c from that prohibition. The PCAC is scheduled to review MOTS-c and six other compounds at the July 23–24, 2026 meeting to evaluate 503A eligibility. Removal from Category 2 does not authorize compounding. WADA added MOTS-c to its prohibited substance list in 2024 under the 'peptide hormones and related substances' category. Any athlete subject to anti-doping testing should treat it as prohibited regardless of its regulatory gray zone status with the FDA.
PROS & CONS
PROS
- +Novel mechanism from a genuinely new class of peptides (mitochondrial-encoded)
- +Animal data for metabolic and longevity effects is consistent and compelling
- +Human observational data provides biological plausibility in humans
- +Endogenous: the body produces it naturally, which limits some toxicity concerns
- +Active research program in academic settings
CONS
- −WADA banned: prohibited in competitive sport
- −No completed human interventional trials for any endpoint
- −Observational correlation with longevity does not prove supplementation works
- −Grey market supply has no quality control
- −Effective dose in humans is entirely unknown
- −No FDA approval, no authorized compounding pathway
DAILY PEPTIDE VERDICT
RANKING
MOTS-c's origin story is genuinely remarkable: a peptide produced by the mitochondria, acting as a retrograde signal that tells the cell how to respond to metabolic stress. The biology is real, the animal data is compelling, and the human observational correlations with longevity are intriguing. The problem is exactly the same one that applies to every grey market longevity compound: 'interesting in animals and observed in correlation studies' is not 'proven in human interventional trials.' WADA's 2024 ban is the regulatory community's bet that it's performance-enhancing, but a ban is not evidence it works. Until a controlled human trial tests an intervention, the path from mechanism to benefit remains theoretical. MOTS-c is worth watching closely as research continues. It is not yet proven.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. MOTS-c does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.